Ciprofloxacin Tablets 500 mg Recall: CGMP Deviations
Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01
What is the FDA recall status?
The FDA record lists this recall as ongoing. FDA enforcement data is not a live recall-lifecycle tracker. Follow the official instructions and check the agency notice or firm for current guidance.
Why was Ciprofloxacin Tablets 500 mg recalled?
CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.
What should I do if I have this product?
Follow the firm and FDA instructions for the affected product. Contact the recalling firm for current guidance.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare your product with the product description and available lot, UPC or model codes below from the official FDA record to check whether it is covered by this recall. If an identifier is missing or unclear, check the complete official notice or contact the firm; an incomplete match here does not establish that your product is unaffected.
Full product description
Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01
Which lot codes, UPCs or models are affected?
Lot# CB496A; Exp. 12/31/2026 Lot# CB497A; Exp. 12/31/2026 Lot# CB498A; Exp. 12/31/2026
- Agency record number
- D-0165-2027
- Product
- Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01
- Recalling firm
- Hikma Pharmaceuticals USA INC.
- Quantity
- 29,085 bottles
- Distribution
- US Nationwide
- Recall started
- October 20, 2026
- Report date
- November 11, 2026
- Classification
- Class II
- Status
- Ongoing
- Agency
- FDA (drug)